Photo: Depositphotos
May 30, 2025, 06:35
Jay Bradner: Molecular Determinants of Sotorasib Clinical Efficacy in KRASG12C-NSCLC
Jay Bradner, Executive Vice President of R&D, and Chief Scientific Officer at Amgen, posted on X:
“A new Nature Medicine study sheds light on why KRAS G12C–mutated NSCLC patients respond differently to treatment. Insights from two trials reveal molecular features and early blood-based markers that may predict outcomes. Grateful to our Amgen team involved.”
Title: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Authors: Ferdinandos Skoulidis, Bob T. Li, Adrianus Johannes de Langen, David S. Hong, Herve Lena, Juergen Wolf, Grace K. Dy, Alessandra Curioni Fontecedro, Pascale Tomasini, Vamsidhar Velcheti, Anthonie J. van der Wekken, Christophe Dooms, Luis Paz-Ares Rodriguez, Giannis Mountzios, Adrian Sacher, Ernest Nadal, Sebastien Couraud, Sang-We Kim, Kenneth O’Byrne, Danilo Rocco, Ryo Toyozawa, Izabela Chmielewska, Colin R. Lindsay, Antreas Hindoyan, Martin Schuler
Read The Full Article at Nature Medicine.
More posts featuring NSCLC.
Adrian Sacher
Adrianus Johannes de Langen
Alessandra Curioni Fontecedro
Amgen
Anthonie J van der Wekken
Antreas Hindoyan
Bob T. Li
cancer
Christophe Dooms
Colin R. Lindsay
Danilo Rocco
David S. Hong
Ernest Nadal
Ferdinandos Skoulidis
Giannis Mountzios
Grace K Dy
Herve Lena
Izabela Chmielewska
Jay Bradner
Juergen Wolf
Kenneth O'Byrne
Luis Paz-Ares Rodriguez
Martin Schuler
NSCLC
OncoDaily
Oncology
Pascale Tomasini
Ryo Toyozawa
Sang-We Kim
Sébastien Couraud
Vamsidhar Velcheti
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 06:25
May 30, 2025, 06:09